Kidney Disease Disparities: eGFR & NYC Public Health
Ozempic and Cardiovascular Risk: New Findings Demand Closer Scrutiny
What Happened? A Closer Look at the SELECT Trial
A major clinical trial, the SELECT trial, has revealed a potential increased risk of cardiovascular events – including heart attack, stroke, and cardiovascular death – in patients with obesity and established cardiovascular disease who were treated with semaglutide (Ozempic) compared too those receiving a placebo. The study, involving over 17,600 participants, initially aimed to determine if semaglutide could reduce the risk of these events, but the results showed a statistically notable, though modest, increase in risk within the treatment group. This finding challenges previous assumptions about the cardiovascular safety of GLP-1 receptor agonists like semaglutide.
Key Findings and Data Breakdown
The SELECT trial followed participants for an average of 3.4 years. The primary composite outcome of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke occurred in 6.5% of patients receiving semaglutide versus 5.8% of those receiving placebo. While the absolute difference is small,the hazard ratio of 1.13 indicates a statistically significant increase in risk. Further analysis revealed increases in both cardiovascular death and nonfatal myocardial infarction,but not stroke.
| Outcome | Semaglutide (6.5%) | Placebo (5.8%) | Hazard Ratio |
|---|---|---|---|
| Cardiovascular Death, MI, or Stroke | 6.5% | 5.8% | 1.13 |
| Cardiovascular Death | 3.7% | 3.2% | 1.16 |
| Nonfatal Myocardial Infarction | 3.7% | 3.0% | 1.23 |
| Nonfatal Stroke | 0.8% | 0.7% | 1.11 |
who is Affected? Understanding the Patient Population
The SELECT trial specifically enrolled adults with obesity (BMI of 30 or higher) *and* established cardiovascular disease - meaning they had a prior heart attack, stroke, or peripheral artery disease. This is a crucial detail. The findings do *not* necessarily apply to individuals using semaglutide for weight loss without pre-existing cardiovascular conditions. However, the results raise concerns for the millions of people with both obesity and heart disease who are increasingly prescribed these medications.
Its vital to note that the study population was predominantly White (84.6%), which limits the generalizability of the findings to other racial and ethnic groups. Further research is needed to determine if the observed cardiovascular risks differ across diverse populations.
What Does This mean? Implications for Patients and physicians
These findings necessitate a reevaluation of the risk-benefit profile of semaglutide for patients with established cardiovascular disease. Physicians should carefully consider a patient’s cardiovascular history before prescribing semaglutide and engage in shared decision-making, thoroughly discussing the potential risks and benefits. Monitoring for cardiovascular events is also crucial in patients already taking semaglutide who fall into this high-risk category.
The study also highlights the importance of lifestyle interventions – diet and exercise – as foundational components of cardiovascular health management, even when medications are used. Semaglutide should not be viewed as a replacement for these essential strategies.